We Are Changing The World by Making The Best Vaccines, Pharmaceuticals, and Nutraceuticals Better.

Learn More

Mountain Valley MD News

Stay up to date on all Mountain Valley MD News and Videos.

Subscribe To Updates

February 22, 2021

First Glance with Jody Vance (E26): Update from Mountain Valley MD (MVMD. C) management team

Button Text

Video

February 22, 2021

First Glance with Jody Vance (E26): Update from Mountain Valley MD (MVMD. C) management team

Watch Video Read Article

Mountain Valley MD adds South African Variant to Bio Safety Level 4 lab study

Video

February 22, 2021

Mountain Valley MD adds South African Variant to Bio Safety Level 4 lab study

Watch Video Read Article

GTA company working on the treatment side of Covid

Article

February 18, 2021

GTA company working on the treatment side of Covid

Watch Video Read Article

Mountain Valley MD Broadens U.S. Investor Outreach With OTC Listing Beginning February 16

Article

February 15, 2021

Mountain Valley MD Broadens U.S. Investor Outreach With OTC Listing Beginning February 16

Watch Video Read Article

Ivermectin: Major tech breakthrough in human application, as scientists aim to save world from Covid-19 and malaria

Article

February 11, 2021

Ivermectin: Major tech breakthrough in human application, as scientists aim to save world from Covid-19 and malaria

Watch Video Read Article

Video

February 1, 2021

First Glance with Jody Vance (E18)

Watch Video Read Article

Mountain Valley MD gets approval for COVID-19 clearance trial in Level 4 Bio Hazard Facility

Video

January 27, 2021

Mountain Valley MD gets approval for COVID-19 clearance trial in Level 4 Bio Hazard Facility

Watch Video Read Article

Mountain Valley MD Patent Filing Creates New Global Delivery And Patient Delivery Model

Video

January 20, 2021

Mountain Valley MD Patent Filing Creates New Global Delivery And Patient Delivery Model

Watch Video Read Article

Mountain Valley MD files a patent for dosed adjuvant with potential application for polio vaccine

Video

January 20, 2021

Mountain Valley MD files a patent for dosed adjuvant with potential application for polio vaccine

Watch Video Read Article

First Glance with Jody Vance (E15): We talk to Mountain Valley MD (MVMD. C) CEO Dennis Hancock

Video

January 18, 2021

First Glance with Jody Vance (E15): We talk to Mountain Valley MD (MVMD. C) CEO Dennis Hancock

Watch Video Read Article

Video

January 11, 2021

“We Can’t Wait Any Longer”

Watch Video Read Article

Mountain Valley MD secures private placement as company looks to take big step forward in 2021

Video

December 22, 2020

Mountain Valley MD secures private placement as company looks to take big step forward in 2021

Watch Video Read Article

Mountain Valley MD outlines upcoming milestones including potential pharma partnerships

Video

December 16, 2020

Mountain Valley MD outlines upcoming milestones including potential pharma partnerships

Watch Video Read Article

Mountain Valley MD, Dennis Hancock President and CEO

Video

December 4, 2020

Mountain Valley MD, Dennis Hancock President and CEO

Watch Video Read Article

MORE LIFE,

LESS DEATH

We are a group of changemakers who work to create a world with more life and less death. A world with more mothers, fathers, sisters, sons, daughters and friends. A world where the ravages of COVID-19, polio, malaria and more… no longer make us and our children, live in masked fear.
‍
We work to create a world where education, business, lives and livelihoods are free from the shackles of sickness and pain and are once more bound by nothing but imagination and possibility…to envision a world where we no longer fear the worst, but see the truth that in fact, the best is yet to come.

With our vision of a better world firmly in sight, we make it our mission (every single day) to realize what is possible with our technology, patents, people and products.

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“This is the best interview Agoracom has done in the last ten years. If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.”

- George Tsiolis, President of Agoracom

“This breakthrough is a major game-changer for the future potential administration of Ivermectin, and perhaps other drug and vaccine applications. Applied to Ivermectin, Mountain Valley’s Quicksome technology greatly improved its therapeutic potential.”

- Benjamin Smith, The Dales Report

“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“Our study will evaluate the ability of MVMD’s new porous aluminum nanostructures to adjuvant injected IPV, promote dose-sparing, and therefore lower costs, and facilitate mucosal and herd immunity when compared to IPV.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“MVMD has developed a tablet that dissolves easily, with a fraction of the dose, of wonder drug Ivermectin.”

- Jackie Cameron, BizNews

“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We designed the study with the goal of providing the first in vivo proof of enhanced COVID-19 viral clearance ability using both the oral sublingual product and the intramuscular injection product using MVMD’s Quicksol™ technology.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“MVMD takes existing vaccines and drugs – and delivers them better. Both into the body and by transportation to the world. Way better.”

- George Tsiolis, President of Agoracom

“MVMD’s technology showed greater pharmacokinetic performance, more rapid onset times, with greater drug distribution and stability in the canines trialled—at 1/5 the dosages compared to existing oral and subcutaneous injection solutions.”

- Benjamin Smith, The Dales Report

“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“The transgenic mice model was selected to specifically enable preclinical evaluation of the potential therapeutics and monoclonal antibodies and molecular-based therapeutics as they apply to COVID-19 treatments.”

Recent News

MOUNTAIN VALLEY MD TO INCLUDE TESTING OF SOUTH AFRICAN MUTATION IN UPCOMING COVID-19 BSL-4 CLEARANCE WORK

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STOCK OPTION GRANT AND WARRANT EXERCISE UPDATE

MOUNTAIN VALLEY MD HOLDINGS TO COMMENCE TRADING ON OTCQB MARKET UNDER TICKER MVMDF

MOUNTAIN VALLEY MD CONTRACTS TULANE UNIVERSITY FOR ADJUVANT IPV STUDY

MOUNTAIN VALLEY MD PROCEEDING WITH COVID-19 CLEARANCE TRIAL IN LEVEL 4 BIOHAZARD FACILITY

MOUNTAIN VALLEY MD FILES PATENT FOR NOVEL VACCINE DOSE SPARING ADJUVANT

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES APPLICATION FOR OTCQB LISTING IN U.S., PROVIDES UPDATE ON WARRANT EXERCISES

MOUNTAIN VALLEY MD COMPLETES STRATEGIC SALE OF SUBSIDIARY, FINALIZING QUICKSOME™ LICENSE AGREEMENT

MOUNTAIN VALLEY MD FILES FOR ACCELERATION OF PATENT EXAMINATION FOR SOLUBILIZED IVERMECTIN

MOUNTAIN VALLEY MD HOLDINGS OVERSUBSCRIBES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS, APPOINTMENT OF ADVISOR BOARD MEMBERS, AND PROPOSED DEBT SETTLEMENT

MOUNTAIN VALLEY MD CONFIRMS 800% INCREASE IN IVERMECTIN ABSORPTION WITH SOLUBILIZATION TECHNOLOGY IN PRE-CLINICAL TRIAL

MOUNTAIN VALLEY MD SECURES QUICKSOME™ LICENSE AGREEMENT AND STRATEGIC SALE OF SUBSIDIARY

MOUNTAIN VALLEY MD FILES PATENT TO PROTECT SCIENCE ACHIEVEMENT IN SOLUBILIZATION OF IVERMECTIN WITHOUT ORGANIC SOLVENTS AND ITS APPLICATION TO COVID-19 AND OTHER THERAPIES

MOUNTAIN VALLEY MD PROVIDES SUCCESSFUL QUICKSOME™ SUBLINGUAL PRE-CLINICAL TRIAL DOSING UPDATE

LEADING VACCINE EXPERT JOINS MOUNTAIN VALLEY MD ADVISORY BOARD TO ADVANCE QUICKSOME™ COMMERCIALIZATION

MOUNTAIN VALLEY MD SECURES DISTRIBUTION RIGHTS FOR NEW AGRICULTURAL PLANT STIMULANT

MOUNTAIN VALLEY MD ANNOUNCES SUCCESSFUL COMPLEXATION OF IVERMECTIN DRUG IN QUICKSOME™ ORAL STRIP AND COMMENCEMENT OF PRE-CLINICAL TRIALS

U.S. FOOD AND DRUG ADMINISTRATION (FDA) POLIO LAB CONFIRMS MOUNTAIN VALLEY MD’S QUICKSOME™ TECHNOLOGY SUCCESSFULLY PRESERVES POLIO D ANTIGEN FOR VACCINES

MOUNTAIN VALLEY MD HOLDINGS’ SUBSIDIARY COMPLETES ACQUISITION OF COLOMBIAN CANNABIS LICENCE SUITE

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES INTELLECTUAL PROPERTY ASSET TRANSFER, SOLIDIFIES QUICKSOME TECHNOLOGY

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES NEW CFO, NEW BOARD MEMBER AND TRANSITION OF PREVIOUS CFO TO ADVISORY ROLE

MOUNTAIN VALLEY MD HOLDINGS INC. PROVIDES UPDATE ON INTELLECTUAL PROPERTY ASSETS, COMPLETES SHARES FOR DEBT TRANSACTION AND GRANT OF OPTIONS

MOUNTAIN VALLEY MD HOLDINGS INC. COMMENCES TRADING ON CSE UNDER TICKER “MVMD”

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES APPROVAL OF CSE LISTING

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES REVERSE TAKEOVER TRANSACTION

We Are Changing The World by Making The Best Vaccines, Pharmaceuticals, and Nutraceuticals Better.

Share This Video

Infinite Possibility.

Mountain Valley MD News

Stay up to date on all Mountain Valley MD News and Videos.

First Glance with Jody Vance (E26): Update from Mountain Valley MD (MVMD. C) management team

First Glance with Jody Vance (E26): Update from Mountain Valley MD (MVMD. C) management team

Mountain Valley MD adds South African Variant to Bio Safety Level 4 lab study

GTA company working on the treatment side of Covid

Mountain Valley MD Broadens U.S. Investor Outreach With OTC Listing Beginning February 16

Ivermectin: Major tech breakthrough in human application, as scientists aim to save world from Covid-19 and malaria

First Glance with Jody Vance (E18)

Mountain Valley MD gets approval for COVID-19 clearance trial in Level 4 Bio Hazard Facility

Mountain Valley MD Patent Filing Creates New Global Delivery And Patient Delivery Model

Mountain Valley MD files a patent for dosed adjuvant with potential application for polio vaccine

First Glance with Jody Vance (E15): We talk to Mountain Valley MD (MVMD. C) CEO Dennis Hancock

“We Can’t Wait Any Longer”

Mountain Valley MD secures private placement as company looks to take big step forward in 2021

Mountain Valley MD outlines upcoming milestones including potential pharma partnerships

Mountain Valley MD, Dennis Hancock President and CEO

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“This is the best interview Agoracom has done in the last ten years. If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.”

- George Tsiolis, President of Agoracom

“This breakthrough is a major game-changer for the future potential administration of Ivermectin, and perhaps other drug and vaccine applications. Applied to Ivermectin, Mountain Valley’s Quicksome technology greatly improved its therapeutic potential.”

- Benjamin Smith, The Dales Report

“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“Our study will evaluate the ability of MVMD’s new porous aluminum nanostructures to adjuvant injected IPV, promote dose-sparing, and therefore lower costs, and facilitate mucosal and herd immunity when compared to IPV.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“MVMD has developed a tablet that dissolves easily, with a fraction of the dose, of wonder drug Ivermectin.”

- Jackie Cameron, BizNews

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We designed the study with the goal of providing the first in vivo proof of enhanced COVID-19 viral clearance ability using both the oral sublingual product and the intramuscular injection product using MVMD’s Quicksol™ technology.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“MVMD takes existing vaccines and drugs – and delivers them better. Both into the body and by transportation to the world. Way better.”

- George Tsiolis, President of Agoracom

“MVMD’s technology showed greater pharmacokinetic performance, more rapid onset times, with greater drug distribution and stability in the canines trialled—at 1/5 the dosages compared to existing oral and subcutaneous injection solutions.”

- Benjamin Smith, The Dales Report

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“The transgenic mice model was selected to specifically enable preclinical evaluation of the potential therapeutics and monoclonal antibodies and molecular-based therapeutics as they apply to COVID-19 treatments.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

Subscribe to Updates from MVMD

Stay plugged in on everything MVMD.